{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T05:11:50Z","timestamp":1768885910951,"version":"3.49.0"},"reference-count":46,"publisher":"FapUNIFESP (SciELO)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq. Gastroenterol."],"published-print":{"date-parts":[[2010,3]]},"abstract":"<jats:p>CONTEXT: No effective treatment is available for nonalcoholic steatohepatitis in nowadays. OBJECTIVES: To develop a model of nonalcoholic steatohepatitis induced by a methionine and choline deficient diet, as well as to evaluate the role of metformin, vitamin E and simvastatin in the nonalcoholic steatohepatitis progression. METHODS: The study analyzed prospectively 50 Wistar rats for a 90-day period and divided them into five groups of 10 rats. One group was given standard rat diet and the others received the methionine and choline deficient diet. Among the four groups that received this diet, one received saline 0,9% and the others received metformin, vitamin E or simvastatin. After the study period, the animals were sacrificed and their blood was collected for biochemical analysis. The livers were removed for lipoperoxidation analysis and for the histological examinations. RESULTS: The methionine and choline deficient diet was able to induce steatosis in 100% of the animals and nonalcoholic steatohepatitis in 27 (69.2%). The alanine aminotransferase levels were significantly higher in the simvastatin group. The aspartate aminotransferase levels were also higher in the simvastatin group, but were statistically significant only in relation to the standard diet group. When lipoperoxidation values were compared, the groups that received standard rat diet and methionine and choline deficient with vitamin E presented significantly lower rates than the others. The presence of fibrosis was significantly smaller in the group receiving vitamin E. CONCLUSIONS: The diet used was able to induce steatosis and nonalcoholic steatohepatitis. Besides vitamin E showed to reduce the liver oxidative stress, as well as the fibrosis development<\/jats:p>","DOI":"10.1590\/s0004-28032010000100015","type":"journal-article","created":{"date-parts":[[2010,5,30]],"date-time":"2010-05-30T19:45:42Z","timestamp":1275248742000},"page":"86-92","source":"Crossref","is-referenced-by-count":12,"title":["The vitamin E reduces liver lipoperoxidation and fibrosis in a model of nonalcoholic steatohepatitis"],"prefix":"10.1590","volume":"47","author":[{"given":"Idilio","family":"Zamin Jr","sequence":"first","affiliation":[{"name":"Funda\u00e7\u00e3o Faculdade Federal de Ci\u00eancias M\u00e9dicas de Porto Alegre, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo Alves de","family":"Mattos","sequence":"additional","affiliation":[{"name":"Funda\u00e7\u00e3o Faculdade Federal de Ci\u00eancias M\u00e9dicas de Porto Alegre, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c2ngelo Zambam de","family":"Mattos","sequence":"additional","affiliation":[{"name":"Funda\u00e7\u00e3o Faculdade Federal de Ci\u00eancias M\u00e9dicas de Porto Alegre, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela","family":"Coral","sequence":"additional","affiliation":[{"name":"Funda\u00e7\u00e3o Faculdade Federal de Ci\u00eancias M\u00e9dicas de Porto Alegre, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diogo","family":"Santos","sequence":"additional","affiliation":[{"name":"Funda\u00e7\u00e3o Faculdade Federal de Ci\u00eancias M\u00e9dicas de Porto Alegre, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cl\u00e1udia","family":"Rhoden","sequence":"additional","affiliation":[{"name":"Funda\u00e7\u00e3o Faculdade Federal de Ci\u00eancias M\u00e9dicas de Porto Alegre, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1056\/NEJMra011775","article-title":"Nonalcoholic fatty liver disease [medical progress]","volume":"346","author":"Angulo P","year":"2002","journal-title":"N Engl J Med."},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/0016-5085(94)90235-6","article-title":"Nonalcoholic steatohepatitis: an explanded clinical entity","volume":"107","author":"Bacon BR","year":"1994","journal-title":"Gastroenterology."},{"key":"ref3","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1111\/j.1572-0241.1999.01377.x","article-title":"Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions","volume":"94","author":"Brunt EM","year":"1999","journal-title":"Am J Gastroenterol."},{"key":"ref4","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1053\/gast.2002.34168","article-title":"Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma","volume":"123","author":"Bugianesi E","year":"2002","journal-title":"Gastroenterology."},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/j.1572-0241.2005.41583.x","article-title":"A randomized controlled trial of metformina versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease","volume":"100","author":"Bugianesi E","year":"2005","journal-title":"Am J Gastroenterol."},{"key":"ref6","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/hep.510240410","article-title":"Clinical hepatology: profile of an urban, hospital-based practice","volume":"24","author":"Byron D","year":"1996","journal-title":"Hepatology."},{"key":"ref7","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/hep.510290347","article-title":"Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease","volume":"29","author":"Caldwell SH","year":"1999","journal-title":"Hepatology."},{"key":"ref8","first-page":"1056","article-title":"Alcohol-like liver disease in nonalcoholics: A clinical and histological comparison with alcohol-induced liver injury","volume":"95","author":"Diehl AM","year":"1988","journal-title":"Gastroenterology."},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1002\/hep.20251","article-title":"Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss","volume":"39","author":"Dixon JB","year":"2004","journal-title":"Hepatology."},{"key":"ref10","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.0954-6820.1986.tb02733.x","article-title":"Nonalcoholic steatohepatitis in obesity: a reversible condition","volume":"220","author":"Eriksson S","year":"1986","journal-title":"Acta Med Scand."},{"key":"ref11","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1093\/jn\/130.9.2131","article-title":"Starvation impairs antioxidant defense in fatty livers of rats fed a choline-deficient diet","volume":"130","author":"Grattagliano I","year":"2000","journal-title":"J Nutr."},{"key":"ref12","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1111\/j.1572-0241.2003.08699.x","article-title":"Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis","volume":"98","author":"Harrison SA","year":"2003","journal-title":"Am J Gastroenterol."},{"key":"ref13","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cld.2004.06.008","article-title":"Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"8","author":"Harrison SA","year":"2004","journal-title":"Clin Liver Dis."},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1046\/j.1365-2036.2001.01083.x","article-title":"Plasma transforming growth factor \u03b21 level and efficacy of \u03b1-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study","volume":"15","author":"Hasegawa T","year":"2001","journal-title":"Aliment Pharmacol Ther."},{"key":"ref15","doi-asserted-by":"crossref","first-page":"A544","DOI":"10.1016\/S0016-5085(08)82704-7","article-title":"Atorvastatin for the treatment of NASH","volume":"120","author":"Horlander JC","year":"2001","journal-title":"Gastroenterology."},{"key":"ref16","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1155\/2003\/857869","article-title":"Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis","volume":"17","author":"Kiyici M","year":"2003","journal-title":"Can J Gastroenterol."},{"key":"ref17","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1053\/jhep.2003.50316","article-title":"Cytokines and a pilot study of the effects of lifestyle modification and vitamin E","volume":"38","author":"Kugelmas M","year":"2003","journal-title":"Hepatology."},{"key":"ref18","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S0022-3476(00)05040-X","article-title":"Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study","volume":"136","author":"Lavine JE","year":"2000","journal-title":"J Pediatr."},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1172\/JCI8814","article-title":"CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis","volume":"105","author":"Leclercq IA","year":"2000","journal-title":"J Clin Invest."},{"key":"ref20","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/79697","article-title":"Metformin reverses fatty liver disease in obese, leptin-deficient mice","volume":"6","author":"Lin HZ","year":"2000","journal-title":"Nat Med."},{"key":"ref21","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0021-9258(19)52451-6","article-title":"Protein measurement with the folin phenol reagent","volume":"193","author":"Lowry OH","year":"1951","journal-title":"J Biol Chem."},{"key":"ref22","first-page":"434","article-title":"Nonalcoholic steatohepatitis","volume":"55","author":"Ludwig J","year":"1980","journal-title":"Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc."},{"key":"ref23","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S0140-6736(01)06042-1","article-title":"Metformin in non-alcoholic steatohepatitis","volume":"358","author":"Marchesini G","year":"2001","journal-title":"Lancet."},{"key":"ref24","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1055\/s-2007-1007110","article-title":"Cytokines in alcoholic liver disease","volume":"19","author":"McClain CJ","year":"1999","journal-title":"Semin Liver Dis."},{"key":"ref25","first-page":"A409","article-title":"HMG-CoA reductase inhibitors in non alcoholic fatty liver disease: is their potential hepatotoxicity an issue in these patients? A case control study based on histology","volume":"36","author":"Nair S","year":"2002","journal-title":"Hepatology."},{"key":"ref26","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1365-2036.2004.02025.x","article-title":"Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial","volume":"20","author":"Nair S","year":"2004","journal-title":"Aliment Pharmacol Ther."},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1002\/hep.1840380427","article-title":"Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-y ligant rosiglitazone","volume":"38","author":"Neuschwander-Tetri BA","year":"2003","journal-title":"Hepatology."},{"key":"ref28","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/BF02777789","article-title":"Clinicopathologic study of alcohol-like liver disease in non-alcoholics; non-alcoholic steatohepatitis and fibrosis","volume":"27","author":"Nonomura A","year":"1992","journal-title":"Gastroenterol Jpn."},{"key":"ref29","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1023\/A:1020523017873","article-title":"Effect of ursodeoxycholic acid on hepatic steatosis in rats","volume":"47","author":"Okan A","year":"2002","journal-title":"Dig Dis Sci."},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1016\/0016-5085(90)91169-7","article-title":"Effect of weight reduction on hepatic abnormalities in overweight patients","volume":"99","author":"Palmer M","year":"1990","journal-title":"Gastroenterology."},{"key":"ref31","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0014-5793(92)81290-3","article-title":"Vitamin E dietary supplementation inhibits transforming growth factor \u03b21 gene expression in the rat liver","volume":"308","author":"Parola M","year":"1992","journal-title":"FEBS."},{"key":"ref32","article-title":"Vitamin E but not glutathione precursors inhibits hepatic fibrosis in experimental NASH exhibiting oxidative stress and mitochondrial abnormalities","volume":"34","author":"Phung N","year":"2001","journal-title":"Hepatology","ISSN":"https:\/\/id.crossref.org\/issn\/0161-0538","issn-type":"print"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/hep.1840110114","article-title":"The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years","volume":"11","author":"Powell EE","year":"1990","journal-title":"Hepatology."},{"key":"ref34","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/hep.20012","article-title":"A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis","volume":"39","author":"Promrat K","year":"2004","journal-title":"Hepatology."},{"key":"ref35","first-page":"817","article-title":"Alcoholic and nutritional fatty liver and cirrhosis","volume":"73","author":"Rogers AE","year":"1973","journal-title":"Am J Pathol."},{"key":"ref36","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/0002-9343(79)90740-X","article-title":"Fatty liver hepatitis and cirrhosis in obese patients","volume":"67","author":"Schaffner F","year":"1979","journal-title":"Am J Med."},{"key":"ref37","first-page":"283","article-title":"Nonalcoholic fatty liver disease","volume":"8","author":"Schaffner F","year":"1986","journal-title":"Prog Liver Dis."},{"key":"ref38","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1111\/j.1365-2036.2005.02420.x","article-title":"A phase 2 clinical trial of metformina as a treatment for non-diabetic pediatric non-alcoholic steatohepatitis","volume":"21","author":"Schwimmer JB","year":"2005","journal-title":"Aliment Pharmacol Ther."},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1002\/hep.1840220616","article-title":"The natural history of nonalcoholic fatty liver: a follow-up study","volume":"22","author":"Teli MR","year":"1995","journal-title":"Hepatology."},{"key":"ref40","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0168-8278(97)80287-5","article-title":"Therapeutic effects of restricted diet and exercise in obese patients with fatty liver","volume":"27","author":"Ueno T","year":"1997","journal-title":"J Hepatol."},{"key":"ref41","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1365-2036.2004.01888.x","article-title":"Metformin in the treatment of patients with non-alcoholic steatohepatitis","volume":"19","author":"Uygun A","year":"2004","journal-title":"Aliment Pharmacol Ther."},{"key":"ref42","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/00005176-200401000-00012","article-title":"Vitamin E treatment in pediatric obesity-related liver disease: a randomized study","volume":"38","author":"Vajro P","year":"2004","journal-title":"J Pediatr Gastroenterol Nutr."},{"key":"ref43","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1002\/hep.1840120505","article-title":"Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors","volume":"12","author":"Wanless IR","year":"1990","journal-title":"Hepatology."},{"key":"ref44","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/S0016-5085(96)70028-8","article-title":"Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation","volume":"111","author":"Weltman MD","year":"1996","journal-title":"Gastroenterology."},{"key":"ref45","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1053\/jhep.2002.32483","article-title":"Nonalcoholic fatty liver disease: an agenda for clinical research","volume":"35","author":"Younossi Z","year":"2002","journal-title":"Hepatology."},{"key":"ref46","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1155\/2002\/534530","article-title":"Non-alcoholic steatohepatitis in nondiabetic obese patients","volume":"16","author":"Zamin IJ","year":"2002","journal-title":"Can J Gastroenterol."}],"container-title":["Arquivos de Gastroenterologia"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/ag\/v47n1\/v47n1a15.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T16:11:31Z","timestamp":1635437491000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0004-28032010000100015&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["S0004-28032010000100015"],"URL":"https:\/\/doi.org\/10.1590\/s0004-28032010000100015","relation":{},"ISSN":["0004-2803"],"issn-type":[{"value":"0004-2803","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3]]}}}